内部人交易雷达

美国 · SEC Form 4 · 快照日期: 2026-10-18 · 构建时间: 2026-10-18 · English

← 美国市场 · 覆盖记录

美国 · SEC FORM 4

Annovis Bio, Inc.

ANVS · NYSE · CIK 0001477845 · Healthcare · Biotechnology

内部人信号

46.7 / 100

1 位买方 · 3 条买入交易行 · $142.8K 买入总额

为什么有这个信号?

买方广度较低
买入规模较低
角色较强
近期性较低
确信度较强
评分构成

每条进度条表示其对当前分数的贡献;权重和公式保持不变。

Cluster+7.0 / 35
买入规模+8.9 / 25
角色+20.0 / 20
近期性+0.8 / 10
确信度+10.0 / 10

哪些因素限制了当前分数?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Purchase activity is becoming less recent
  • ✓ 角色得分高 · 买入者中职位最高的是:Director

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后,不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。

内部人活动时间轴

申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。

AprMayJunJulAugSepOct
Hoffman Michael BDirector
●
● 买入▼ 卖出○ 其他

—

买方广度与集中度

合资格买方1
买入集中度100%最大买方: Hoffman Michael B · $142.8K
聚集买入 · 15天1 insider峰值活动: 2026-05-20–2026-05-20

Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.

信号历史

46.7 / 100

最新留档分数

↓ -0.1 pts相对上一个留档快照
  1. 46.9
  2. 46.8
  3. 46.8
  4. 46.8
  5. 46.7

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

近期 Form 4 活动

19买入
0卖出
0其他 Form 4 交易行
9SEC 申报 · 365天
买入3 qualifying P line(s) · 180 days
卖出0 sale line(s) · 仅供背景
其他0 exercise / withholding / award / gift / other lines
10b5-1/计划交易Not assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

市场背景

市场背景补充近期价格表现与风险信息,不影响内部人信号。

价格表现

1M
+1.7%
3M
-31.2%
6M
-23.9%
12M
-46.7%

波动率与流动性

波动率
94.2%
Beta
—
平均每日成交额
USD 1.1M

估值

市值
USD 51.6M
P/E
—

基本面

利润率
—
ROE
-171.2%
细分行业
Biotechnology

市场数据

价格数据截至:2026-10-11 · 价格来源:OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件:市值, ROE · 财年截止日:2025-12-31 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期:2026-08-14 · Status: PASS

空头余额

空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。

空头股数
5,895,922
上期报告
6,022,040
日均成交量
990,573
回补天数
6.0

FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。

历史股票买入

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting owner类型证券股数平均价格估算金额来源
2026-05-20Hoffman Michael B买入 (P)Common Stock76,344USD 1.87USD 142,784SEC 申报 ↗
2026-04-02Hoffman Michael B买入 (P)Common Stock713,800USD 2.10USD 1,498,980SEC 申报 ↗
2025-12-08Hoffman Michael B买入 (P)Common Stock45,000USD 4.31USD 193,800SEC 申报 ↗
2025-11-24Hoffman Michael B买入 (P)Common Stock39,200USD 4.08USD 159,886SEC 申报 ↗
2025-11-24Hoffman Michael B买入 (P)Common Stock39,200USD 4.08USD 159,886SEC 申报 ↗
2025-11-21Hoffman Michael B买入 (P)Common Stock20,000USD 3.50USD 69,900SEC 申报 ↗
2025-11-14Hoffman Michael B买入 (P)Common Stock15,000USD 2.11USD 31,650SEC 申报 ↗
2025-10-28Maccecchini Maria-Luisa买入 (P)Common Stock97,561USD 2.05USD 200,000SEC 申报 ↗
2025-10-28Hoffman Michael B买入 (P)Common Stock975,610USD 2.05USD 2,000,000SEC 申报 ↗
2021-10-12White Mark K.买入 (P)Common Stock5,000USD 27.40USD 137,000SEC 申报 ↗
2021-10-11Maccecchini Maria-Luisa买入 (P)Common Stock18,000USD 27.61USD 496,980SEC 申报 ↗
2021-10-11Bruck Claudine买入 (P)Common Stock181USD 27.66USD 5,006SEC 申报 ↗
2021-08-19McCarthy Reid买入 (P)Common Stock, $0.0001 par value500USD 37.61USD 18,805SEC 申报 ↗
2020-02-03McGroarty Jeffrey Brian买入 (P)Common Stock19,500USD 7.15USD 139,428SEC 申报 ↗
2020-01-31White Mark K.买入 (P)Common Stock1,734USD 6.00USD 10,404SEC 申报 ↗

Form 4 申报证据

19 transaction lines in the latest 365-day window; 88 in local history.

日期申报人类型证券股数平均价格估算金额来源
2026-05-20Hoffman Michael B买入 (P)Common Stock76,344USD 1.87USD 142,784SEC 申报 ↗
2026-04-02Hoffman Michael B买入 (P)Common Stock713,800USD 2.10USD 1,498,980SEC 申报 ↗
2025-12-08Hoffman Michael B买入 (P)Common Stock45,000USD 4.31USD 193,800SEC 申报 ↗
展开近期 Form 4 证据 (9 grouped rows)
日期申报人类型证券股数平均价格估算金额来源
2026-05-20Hoffman Michael B买入 (P)Common Stock76,344USD 1.87USD 142,784SEC 申报 ↗
2026-04-02Hoffman Michael B买入 (P)Common Stock713,800USD 2.10USD 1,498,980SEC 申报 ↗
2025-12-08Hoffman Michael B买入 (P)Common Stock45,000USD 4.31USD 193,800SEC 申报 ↗
2025-11-24Hoffman Michael B买入 (P)Common Stock39,200USD 4.08USD 159,886SEC 申报 ↗
2025-11-24Hoffman Michael B买入 (P)Common Stock39,200USD 4.08USD 159,886SEC 申报 ↗
2025-11-21Hoffman Michael B买入 (P)Common Stock20,000USD 3.50USD 69,900SEC 申报 ↗
2025-11-14Hoffman Michael B买入 (P)Common Stock15,000USD 2.11USD 31,650SEC 申报 ↗
2025-10-28Maccecchini Maria-Luisa买入 (P)Common Stock97,561USD 2.05USD 200,000SEC 申报 ↗
2025-10-28Hoffman Michael B买入 (P)Common Stock975,610USD 2.05USD 2,000,000SEC 申报 ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

快照与身份

快照日期2026-10-18
排名版本US-v1.2
数据质量PASS ELIGIBLE · —
股票代码ANVS
CIK0001477845
行业Healthcare
细分行业Biotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
交易所NYSE

数据覆盖

本地 Form 4 历史88 transaction lines from 2020-01-31 to 2026-05-20
31 P purchase lines · 0 S sale lines · 57 other lines
SEC 公司申报打开 SEC 申报 ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.